Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

被引：0
|
作者：
Schultz, R. [1 ]
Diakite, I. [2 ]
Carter, J. [2 ]
Snedecor, S. [2 ]
Turpin, R. [3 ]
机构：
[1] Takeda Pharmaceut USA Inc, Gastroenterol, Deerfield, IL USA
[2] Pharmerit Int, Gastroenterol, Bethesda, MD USA
[3] Takeda Pharmaceut USA Inc, Gastroenterol, Lake Zurich, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 50 条
  • [41] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [42] Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
    Petryszyn, Pawel
    Ekk-Cierniakowski, Pawel
    Zurakowski, Grzegorz
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [43] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY
    Quon, P.
    Sardesai, A.
    Milev, S.
    DiBonaventura, M.
    Cappelleri, J. C.
    Kisser, A.
    Modesto, I
    Dietz, L.
    Dignass, A.
    Bargo, D.
    VALUE IN HEALTH, 2019, 22 : S617 - S617
  • [44] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [45] Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
    Kim, J. S.
    Leung, W. K.
    Wu, D. C.
    Lindner, D.
    Fadeeva, O.
    Demuth, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S431 - S431
  • [46] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis (vol 35, pg 412, 2015)
    Dulai, P. S.
    Mosli, M.
    Khanna, R.
    Levesque, B. G.
    Sandborn, W. J.
    Feagan, B. G.
    PHARMACOTHERAPY, 2015, 35 (10): : 977 - 977
  • [47] Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2016, 32 (7) : 265 - 275
  • [48] Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis
    Venugopal, K.
    Reinisch, W.
    Vermeire, S.
    Hedin, C.
    Rubin, D. T.
    Panes, J.
    Deng, H.
    Xuan, S.
    Wegrzyn, L.
    Liu, J.
    Ilo, D.
    Zhou, W.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 135 - 135
  • [49] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
    Shin, S. Shin
    Park, S. J.
    Kim, Y.
    Im, J. P.
    Kim, H. J.
    Lee, K. M.
    Kim, J. W.
    Jung, S. A.
    Lee, J.
    Kang, S. B.
    Shin, S. J.
    Kim, E. S.
    Kim, Y. S.
    Kim, T. O.
    Kim, H. S.
    Park, D. I.
    Kim, H. K.
    Kim, E. S.
    Kim, Y. H.
    Kim, D. H.
    Teng, D.
    Kim, J. H.
    Kim, W. Y.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
  • [50] Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
    Salcedo, Jonathan
    Hill-McManus, Daniel
    Hardern, Chloe
    Opeifa, Oyin
    Viti, Raffaella
    Siviero, Ludovica
    Roscini, Antonio Saverio
    Di Martino, Gennaro
    PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 701 - 714
12345